ArticleDiscover oncology2025
Mapping the future: bibliometric analysis of omics research trends in non-small cell lung cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeOmics technologies, such as genomics, transcriptomics, proteomics, and radiomics, play an increasingly important role in the diagnosis and treatment of non-small cell lung cancer (NSCLC). It is, therefore, essential to unveil the research landscape and future trends of relevant research. This study aims to explore the research fields based on omics technologies in NSCLC, elucidating the research status, hotspots, and trends from a bibliometric perspective.
methodsThe Web of Science Core Collection was utilized to retrieve relevant publications in omics technologies and their applications in NSCLC. By using the bibliometric methods and tools ("bibliometrix" R package, VOSviewer, and CiteSpace), data and visualized analyses for annual publication outputs, countries, institutions, authors, journals, references, and keywords proceeded.
resultsA total of 5,337 publications were involved in our analysis. These articles, written by 32,286 authors, originated in 5,863 institutions from 82 countries and were published in 797 journals. The Journal of Thoracic Oncology and Clinical Cancer Research were representative journals in omics-based research in NSCLC. "Survival," "adenocarcinoma," "mutation," "epidermal growth factor receptor," "resistance," and "chemotherapy" were the highest-frequency keywords. Liquid biopsy and deep learning were also trending topics in omics-related research, according to keyword clustering, trend topics, and citation burst analysis.
conclusionOmics technologies, including genomics, transcriptomics, and proteomics, were widely used in the diagnosis, prognosis, and treatment of NSCLC. And innovative methods, including liquid biopsy and deep learning, demonstrate a profound impact on advancing the understanding and treatment strategies for NSCLC and warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.